基础化工行业周报：合成生物学周报：化销华中实现生物基产品突破，PEF生产商Avantium签署供应协议

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security [1] - The synthetic biology index, compiled by Huazhong Securities, consists of 58 listed companies involved in synthetic biology and related technologies, covering various sectors including chemicals, pharmaceuticals, and food [1] - The Huazhong synthetic biology index decreased by 4.13% to 1121.50 during the week of October 21-25, 2024, underperforming compared to the Shanghai Composite Index and the ChiNext Index by 5.30% and 6.13%, respectively [1] Summary by Sections 1. Synthetic Biology Market Dynamics - The overall performance of synthetic biology stocks was poor, with a decline of 4.13% during the week of October 21-25, 2024, ranking 32nd among sectors [7] - Top-performing companies included Dongfang Group (+43%), Yabn Chemical (+40%), and Fuxiang Pharmaceutical (+25%) [7] - The report notes that financing for synthetic biology companies is accelerating, with nearly a hundred companies completing new financing rounds since the beginning of 2024 [13] 2. Company Business Progress - Huazhong's synthetic biology report mentions significant developments such as Huaxiao Huazhong's successful sale of the first domestic bio-based benzene product, contributing to the green brand of Sinopec [1][2] - Avantium signed a supply agreement with Royal Vezet to produce salad bowls using bio-based PEF materials, marking a significant step in sustainable packaging [2] - Cureverse signed a global exclusive option agreement for its brain health candidate drug CV-01 with AngeliniPharma, which includes potential milestone payments of up to $360 million [2] 3. Industry Financing Tracking - Element Driven completed nearly 200 million RMB in A-round financing, with funds primarily allocated for technology research and market promotion [13] - MicroLub secured £3.5 million in seed funding to support the commercialization of low-calorie food alternatives [13] - The report indicates that financing activities are robust, with various companies in the synthetic biology sector receiving significant investments to enhance their technological capabilities and market reach [13]